About Monrol
Monrol was founded in 1995 in Kuwait City, Kuwait, as a manufacturer in the radiopharmaceutical sector. Operations include production of lutetium-177 and related products, supported by a global logistics network and manufacturing facilities. Tailor-made solutions for drug development are provided, along with supply services through international affiliates, focusing on theranostic applications.
- Headquarter Kuwait City, Kuwait
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Eczacıbaşı-Monrol
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
Curium
(Mar 28, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Monrol
Detailed funding history for Monrol
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Monrol
Monrol has secured backing from 1 investor. Prominent investors backing the company include Curium Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Curium Pharma is recognized as a leader in radiopharmaceuticals.
|
Locked | Locked | Locked |
Investor details for Monrol
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Monrol
Investment portfolio details for Monrol
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Monrol
Detailed financials for Monrol
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Monrol Comparisons
Peer comparison for Monrol
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Monrol
Detailed competitors of Monrol
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Monrol
Complete news archive for Monrol
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Monrol
Monrol was founded in 1995.
Monrol is headquartered in Kuwait City, Kuwait.
Monrol was founded in 1995 in Kuwait City, Kuwait, as a manufacturer in the radiopharmaceutical sector. Operations include production of lutetium-177 and related products, supported by a global logistics network and manufacturing facilities. Tailor-made solutions for drug development are provided, along with supply services through international affiliates, focusing on theranostic applications.
Monrol has 1 investor. Key investors include Curium Pharma.